Autres langues Clinuvel Pharmaceuticals Limited

Actions

CUV

AU000000CUV3

Temps Différé Australian S.E. Autres places de cotation 02:42:27 08/05/2024			Varia. 5j.	Varia. 1 janv.
15,52 ^AUD	+0,84 %		+2,86 %	-3,19 %

14/03	Clinuvel Pharmaceuticals lance un programme de rachat d'actions	MT
14/03	CLINUVEL PHARMACEUTICALS LIMITED : Morgans Financial désormais positif sur le dossier	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Clinuvel Pharmaceuticals Obtains Orphan Drug Designation in Europe for Xeroderma Pigmentosum Treatment; Shares Up 3%	29/04
Photomedicine Pioneer CLINUVEL Unveils Clinical, Cosmetic Ambitions to German Investors	28/03
Clinuvel Pharmaceuticals Launches Share Buyback Program	14/03
Clinuvel Pharmaceuticals Limited announces an Equity Buyback for 1,500,000 shares, representing 2.99% of its issued share capital.	14/03
Clinuvel Pharmaceuticals Limited authorizes a Buyback Plan.	14/03
Biotech-Unternehmen CLINUVEL launcht Photomedizin-Stiftung bei Event von Lady Gaga	07/03
Malibu shines a light on CLINUVEL’s pioneering work in photomedicine	05/03
Clinuvel Reports Positive Results in SCENESSE Study	04/03
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended December 31, 2023	21/02
Clinuvel Pharmaceuticals Limited Announces Change to Registered Office	07/12
Clinuvel Doses First Patient in Phase 3 Trial of Vitiligo Treatment	18/10/23
Clinuvel Pharmaceuticals Limited Announces Board Changes	29/09/23
Clinuvel Pharmaceuticals Teams Up With Vitiligo Experts to Assess Scenesse	13/09/23
Clinuvel Pharmaceuticals Limited Announces Dividend for the Full Year Ended June 30, 2023, Payable on September 20, 2023	29/08/23
Clinuvel Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended June 30, 2023	29/08/23
Clinuvel Pharmaceuticals Secures Supply Contract for Porphyria Medication with the US Department of Veterans Affairs	26/07/23
Clinuvel Pharmaceuticals Secures Patents for Melanocortins for Treatment of Central Nervous System Disorders	14/07/23
Clinuvel Pharmaceuticals Treats First Patient in Phase Two Stroke Trial	20/03/23
Clinuvel Pharmaceuticals Limited Announces Technical Note - CUV803 Study and AIS	20/03/23
Clinuvel Pharmaceuticals Limited Announces First Stroke Patient Treated with PRENUMBRA Instant	19/03/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Clinuvel Pharmaceuticals Limited

Actions

CUV

AU000000CUV3

Autres langues

Filtres